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Abstract
Background: Schizophrenia is a heterogeneous disorder with diverse presentations. The current and the proposed DSM-V
diagnostic system remains phenomenologically based, despite the fact that several neurobiological and neuropsychological
markers have been identified. A multivariate approach has better diagnostic utility than a single marker method. In this
study, the mismatch negativity (MMN) deficit of schizophrenia was first replicated in a Han Chinese population, and then the
MMN was combined with several neuropsychological measurements to differentiate schizophrenia patients from healthy
subjects.
Methodology/Principal Findings: 120 schizophrenia patients and 76 healthy controls were recruited. Each subject received
examinations for duration MMN, Continuous Performance Test, Wisconsin Card Sorting Test, and Wechsler Adult
Intelligence Scale Third Edition (WAIS-III). The MMN was compared between cases and controls, and important covariates
were investigated. Schizophrenia patients had significantly reduced MMN amplitudes, and MMN decreased with increasing
age in both patient and control groups. None of the neuropsychological indices correlated with MMN. Predictive
multivariate logistic regression models using the MMN and neuropsychological measurements as predictors were
developed. Four predictors, including MMN at electrode FCz and three scores from the WAIS-III (Arithmetic, Block Design,
and Performance IQ) were retained in the final predictive model. The model performed well in differentiating patients from
healthy subjects (percentage of concordant pairs: 90.5%).
Conclusions/Significance: MMN deficits were found in Han Chinese schizophrenia patients. The multivariate approach
combining biomarkers from different modalities such as electrophysiology and neuropsychology had a better diagnostic
utility.
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Introduction
Schizophrenia is recognized as a neurobiological syndrome with
heterogeneous presentation and pathophysiology. The develop-
ment of biological markers is important in schizophrenia research,
which is restricted by the phenomenology-based diagnostic system.
Biological markers are measurable traits that are specific to
particular conditions and have diagnostic and predictive values.
Several measurements have been reported to discriminate
schizophrenia patients from healthy controls, such as quantitative
electroencephalography and event-related potentials (ERP) [1].
However, a single marker may not be able to address the
heterogeneous nature of schizophrenia.
Mismatch negativity (MMN) is a negative component of
auditory event-related potentials elicited when infrequent discern-
ible deviant sounds (‘‘oddballs’’) occur in a sequence of repetitive
standard sounds. The MMN response relies on the established
memory trace of standard sounds and is an index of automatic
pre-attentive sensory processing of auditory input and echoic
memory [2–6]. MMN deficit has been shown to be a robust
feature for chronic schizophrenia patients [7] and is regarded as a
candidate endophenotype for schizophrenia [8,9]. Some studies
suggested that MMN deficit is specific to schizophrenia [10–14]
and is unrelated to neuroleptics treatment [15–19]. However,
MMN deficit has ever been observed for subjects with bipolar
disorder [20–21] or Asperger syndrome [22–24]. Furthermore,
MMN alone may not be adequate to predict whether an
individual subject has schizophrenia or not. The effect size of
MMN deficit for schizophrenia is around 0.99, and it implies that
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5the distributions of MMN of controls and schizophrenia patients
overlap [7]. In the literature, only one study has applied MMN in
the context of multivariate electrophysiological endophenotype
approach (MMN, P50, P300, and antisaccades) to predict the
diagnostic groups [25]. The study found that a weighted
combination of the four markers could provide better power in
prediction. In addition to the multivariate approach, using
markers measured by different modalities may improve the
predictive power further [26]. To date, there have been no study
on MMN in Han Chinese schizophrenia patients. The current
study thus aims to evaluate the performance of combining MMN
with neuropsychological tests to differentiate schizophrenia
patients from healthy subjects in a population of Han Chinese
Ethnicity.
The pattern of discriminating schizophrenia patients from
healthy subjects by MMN is related to the types of deviant stimuli
and aging. Todd et al. showed that patients at the early course of
schizophrenia had deficits in duration and intensity MMN, but not
frequency MMN. With longer length of illness, the frequency
MMN deficit became significant [27]. Frequency MMN deficits
were not found in first-episode schizophrenia patients [28–30] or
patients with recent-onset schizophrenia [31]. One study found
significant reduction in chronic schizophrenia patients and
marginal reduction in recent-onset schizophrenia patients for
both duration and frequency MMN [31]. Marginally decreased
duration MMN amplitudes, rather than frequency MMN was
noted for subjects exhibiting prodromal symptoms of schizophre-
nia [32]. These studies suggested MMN deficits are related to the
progression of schizophrenia, and duration MMN might be a
more sensitive marker in the early stage of the disease. However,
two studies were unable to find duration MMN deficits in first-
episode schizophrenia patients [29,30]. In addition, the age-
related declination of MMN observed in healthy subjects further
complicated the interpretation of progressive MMN reduction
with the course of schizophrenia [33–38]. Salisbury et al.
conducted a follow-up study for a group of first-hospitalized
schizophrenia patients. Frequency MMN amplitude of schizo-
phrenia patients was not different from age-matched controls
initially, but 1.5 years later patients showed significant MMN
reduction which was correlated with the reduction of left Heschl’s
gyrus gray matter [39]. The study by Todd et al. found significant
age-related decline of duration MMN for both healthy subjects
and schizophrenia, but the age-related decline of frequency MMN
was only observed in schizophrenia patients [27]. Similarly, Kiang
et al. also found age-related decline of duration MMN for both
controls and schizophrenia patients [40]. In summary, with the
course of schizophrenia, the duration MMN deficit remains stable
and its gradual reduction seems to be related to aging. To the
contrary, frequency MMN is related more to the progression of
pathology of schizophrenia. Therefore, we chose to look at
duration MMN for the prediction of diagnostic groups.
Cognitive impairment is a core feature of schizophrenia, with
high intra-group heterogeneity [41]. The effect size of a single
neuropsychological test to differentiate patients from healthy
controls has been reported to be around 0.46 to 1.57, with the
largest effects in global verbal memory and processing speed
measured by digit symbol coding [42,43]. But the distribution of
test scores of schizophrenia patients overlapped with that of
healthy subjects, and no single test was able to satisfactorily
separate the two groups. The Continuous Performance Test (CPT)
and Wisconsin Card Sorting Test (WCST) are two neuropsycho-
logical tests widely applied in the research of schizophrenia. The
CPT is an index of sustained attention, early visual information
processing, and response inhibition. During the CPT session,
numbers from 0 to 9 are randomly presented to the subjects. They
need to respond whenever the number ‘‘9’’ appears following the
number ‘‘1’’. The WCST is used as a complex measurement of
executive function, where mental flexibility, working memory, and
goal-directed behaviors are involved. The WCST requires subjects
to match a series of 128 response cards one by one to the stimulus
cards according to color, form, or number. After each trial, ‘‘right’’
or ‘‘wrong’’ is fed-back without telling the correct sorting principle.
Subjects have to figure out the right principle and correctly
complete 10 consecutive trials. Then the sorting rule changes, and
subjects need to find the new rule. Schizophrenia patients have
poorer performance on both the CPT and WCST, with reported
effect sizes of 0.66 to 1.13 and 0.81 to 1.00 respectively [42].
In this study, we applied a multivariate approach to classify
schizophrenia patients and healthy subjects using MMN and
several neuropsychological markers (CPT, WCST, and the
intelligence test). We first explored the MMN deficit and potential
covariates. On developing the predictive model, the correlation
between the two groups of markers were analyzed. Then in logistic
regression modeling, useful predictive markers were selected and
combined to construct a probability model to predict diagnostic
grouping.
Results
Subjects
Comparisons of demographics and neuropsychological tests
between the schizophrenia patients and healthy subjects are shown
in Table 1. The mean Positive And Negative Syndrome Scale
(PANSS) score of the patients was 53.0615.1. Twenty percent of
them received first generation antipsychotics, 62.5% received
second generation antipsychotics, and the remaining 17.5%
received clozapine. The mean chlorpromazine equivalent dose
was 379.86243.9 mg/day.
Mismatch negativity
Grand average MMN waveforms for each group are shown in
Figure 1. Repeated-measures ANOVA showed a significant main
effect of group (F(1,182)=6.57, p=0.0112) and electrode x group
interaction (F(31,5642)=11.78, p,0.0001, Huynh-Feldt
e=0.1268) on MMN across electrodes. Age was a significant
covariate (age main effect: F(1,182)=10.41, p=0.0015; age x
electrode: F(31,5642)=13.85, p,0.0001, e=0.1268) and was thus
included in following analyses. In both schizophrenia and control
groups, amplitudes of MMN reduced with increasing age, and the
regression coefficients were not different between groups
(t=20.89, df=1, p=0.3746) (Figure 2). Duration of illness was
not a significant covariate after controlling for the effect of age.
The MMN amplitudes at individual electrodes and their effect
sizes are shown in Table 2. The largest effect size was seen at
electrode FCz. The midline analysis showed more negative MMN
frontally in both groups (electrode main effect: F(5,950)=53.41,
p,0.0001, e=0.3245). MMN peaked at FCz in control group and
at Fz in schizophrenia group. MMN at frontal electrodes was not
correlated with any neuropsychological tests or PANSS scores.
Prediction model
MMN at frontal electrodes was not correlated with any
neuropsychological tests (Table 3) or PANSS scores. Table 4
showed the multiple logistic regression model to predict from
which group a subject came. The weighted combination of four
factors, MMN amplitude at FCz, block design, arithmetic and
performance IQ, could best differentiate the patient group from
the control group and fit the observed data well. When using
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concordant pairs was only 70.0%, and the adjusted generalized R
2
was only 0.17.
Discussion
Our study confirmed MMN deficit of schizophrenia in a Han
Chinese population. In concordance with previous studies,
duration MMN declined with aging in both schizophrenia patients
and controls [27,40]. Since the baseline MMN amplitude is
smaller in schizophrenia patients, the slower declination rate could
be due to the ‘‘floor effect’’ [40]. Interestingly, the aging effects on
MMN were reported to be related to the length of interstimulus
interval. Compared with younger subjects, elder subjects had
significantly attenuated MMN when the interstimulus intervals
were 4.5 seconds. The aging effects were not evident when
interstimulus intervals were only 0.5 seconds [44]. Duration of
illness and the chlorpromazine-equivalent dose were uncorrelated
with duration MMN after correcting for age.
MMN was not correlated with any of the neuropsychological
tests. Several studies have explored the correlation between MMN
and neuropsychological tests in small samples of subjects (see
Table S1). WCST and CPT were generally uncorrelated with
MMN indices, and only Toyomaki et al. reported the duration
MMN mean amplitude to be associated with WCST perseverative
errors [45]. It is noteworthy that different MMN paradigms and
indices yielded different results. For example, Kawabulo et al.
found that phonetic duration MMN was correlated with the Rey
Auditory Verbal Learning Test, while tone duration MMN was
not [46]. Baldeweg et al. found that the MMN memory trace
effect, rather than MMN amplitude, was correlated with verbal
digit span and pre-morbid verbal intelligence [2].
The weighted combination of MMN and neuropsychological
tests enhanced the diagnostic power to differentiate schizophrenia
patients from controls. To the best of our knowledge, this is the
first study to evaluate the combination of electrophysiological
markers and cognitive function for diagnostic purposes. According
to previous meta-analyses, the effect sizes of the selected predictors
were 1.18 for Arithmetic, 0.46 to 0.84 for Block Design, 1.26 for
Performance IQ, and 1.23 for duration MMN [7,42,43]. Digit
symbol has been reported to have the largest effect size, but it was
not selected by the prediction model [42]. There are several
reasons why a covariate will be dropped from a prediction model.
For example, it may have no effect on the response variable after
adjusting for the effects of the other covariates. Further, the
correlation of a variable with other covariates can result in
collinearity and multicollinearity problems in the regression
model.
Our prediction model gave each subject an estimated
probability of having schizophrenia, which is unlike the traditional
cut-off point method to assign subjects to categorical groups. The
probabilistic nature made the prediction model a dimensional
assessment, which is emphasized in the proposed Diagnostic and
Statistic Manual, fifth edition [47]. The new diagnostic system
recognizes cognitive impairment as an important symptom of
schizophrenia. However, cognitive impairment is not included as a
criteria A symptom due to the lack of diagnostic specificity. For
example, Bora et al. argued that the profiles, severity, relationship
with clinical states, and prevalence of cognitive impairments do
not help to differentiate schizophrenia from other major psychotic
disorders. Further, early intellectual declination of cognition exists
in a small portion of patients with schizophrenia [48]. Incorpo-
rating MMN into the ‘‘broad’’ cognitive assessment could
therefore be valuable. MMN impairment is relatively specific to
schizophrenia. Abnormal MMN has not been observed in patients
with bipolar affective disorder, major depressive disorder or
schizoaffective disorder [13,14]. In addition, MMN and neuro-
psychological tests are independent and measured by different
constructs. A combination of cognitive measures with MMN may
thus enhance the differential ability and better address the
heterogeneous nature of schizophrenia.
There are several limitations of this study. First, only
schizophrenia patients and healthy subjects were compared. The
enhanced diagnostic specificity should also be evaluated by
comparing schizophrenia to other major psychotic and affective
disorders. Second, the subjects were mainly chronic schizophrenia
patients, and the results may not be readily applied to first-episode
or prodromal subjects. Third, the validity and reliability of the
prediction model should be tested in another independent sample.
Fourth, all patients in this study were taking psychotropic agents. It
could be possible that the prediction model worked by
differentiating subjects taking or not taking psychotropic agents,
but not subjects with or without schizophrenia. Drug challenge
studies in healthy subjects showed that benzodiazepines increased
MMN latency [49] and decreased MMN amplitudes [50], and
selective serotonin reuptake inhibitors such as escitalopram
increased the MMN amplitude [51]. Dopaminergic agents did
not influence MMN [52]. In schizophrenia patients, treatment
with antipsychotic agents [15–19] or benzodiazepines [53,54] had
no effect on MMN, hence the MMN deficit in schizophrenia may
Table 1. Demographic data and clinical correlates.
Characteristics Control Schizophrenia P value
Female – no. (%) 46 (60.5) 62 (51.7) 0.241
Age – years 36.2561.12 37.9669.83 0.264
Education – years 15.7363.52 13.0862.84 ,0.001
*
Smoking – PPD 0.04860.20 0.1760.41 0.016
*
CPT
d92 0.0361.06 20.6861.20 ,0.001
*
md92 0.0860.99 20.9061.32 ,0.001
*
WCST
Perseverative errors 20.1360.95 0.7861.43 ,0.001
*
Categories achieved 0.3761.05 20.5061.04 ,0.001
*
Trials to complete first category 0.0460.91 0.4761.19 0.010
*
Conceptual level response 0.2661.05 20.6261.15 ,0.001
*
WAIS-III
Arithmetic 11.9663.15 8.2263.23 ,0.001
*
Digit Span 12.3863.14 9.7664.15 ,0.001
*
Information 11.9962.92 10.0763.23 ,0.001
*
Digit Symbol-coding 11.9062.92 10.46612.81 0.350
Block Design 11.8662.88 10.0366.87 0.034
*
Working Memory Index 112.14615.30 92.10617.57 ,0.001
*
Verbal IQ 112.67616.22 94.53617.08 ,0.001
*
Performance IQ 113.06616.56 90.61616.84 ,0.001
*
Full Scale IQ 112.25618.88 92.52615.63 ,0.001
*
*Significant difference between controls and patients with schizophrenia
(significant level at 0.05)Independent t test for continuous variables.
Pearson’s chi-square (2-sided) test for categorical variables.
PPD: package per day.
d9: sensitivity index of undegraded CPT.
md9: sensitivity index of degraded CPT.
doi:10.1371/journal.pone.0034454.t001
Differentiation by MMN and Neuropsychology
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34454not be the result of medications. Further, second-generation
antipsychotics have modest effects on improving cognitive function
[55–57], although first-generation antipsychotics have no or even
adverse cognitive effects [57]. Therefore, drug effects seemed to
have little influence on the prediction model and the group
difference of MMN.
In summary, MMN deficit was a robust phenomenon for Han
Chinese schizophrenia patients, and duration MMN decline with
increasing age in both schizophrenia patients and healthy subjects.
A combination of electrophysiological and neurocognitive markers
better differentiated schizophrenia patients from healthy subjects.
The multivariate phenotype approach delineated the heteroge-
neous nature of schizophrenia. As a measurement with good
specificity for schizophrenia, future studies should evaluate the
value of duration MMN in developing composite diagnostic
batteries.
Materials and Methods
Subjects
One hundred and twenty stable outpatients, aged 18 to 65 years
who met the DSM-IV criteria for schizophrenia, and 76 age- and
gender-matched healthy controls were recruited. The study was
approved by the Institutional Review Board of the National
Taiwan University Hospital. Written informed consent was
received from all participants. Each schizophrenia patient’s
capacity to consent was evaluated by his/her treating psychiatrist
who made the referral to this study. When the capacity to consent
was reduced, consent from another family member was required
in addition to the patient’s consent. All subjects were interviewed
using the Chinese version of the Diagnostic Interview for Genetic
Studies (DIGS) [58]. Then two board-certified psychiatrists
independently made the diagnoses according to the DSM-IV-
TR criteria by reviewing the DIGS data and medical charts. If the
Figure 1. Grand average mismatch negativity waveforms. (A) Grand average mismatch negativity waveform at each electrode shown for
schizophrenia patients (red line) and healthy subjects (blue line). The mismatch negativity waveform reversed in polarity at the mastoid electrodes.
(B) Grand average MMN waveform at electrode Fz. (C) Grand average MMN waveform at electrode FCz.
doi:10.1371/journal.pone.0034454.g001
Differentiation by MMN and Neuropsychology
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34454diagnoses were inconsistent, a senior psychiatrist would made the
final diagnoses. Subjects with mental retardation, schizoaffective
disorders, bipolar affective disorder, organic mental disorders, and
substance-related disorders were excluded. The controls had no
lifetime or current psychiatric diagnosis or family history of
psychotic disorders. Subjects were excluded if they had epileptic
disorders or other major brain pathology. The age of onset and
Positive And Negative Syndrome Scale (PANSS) scores were
recorded for the patients [59]. In addition, daily doses of
antipsychotic agents were transformed into chlorpromazine
equivalents by the formulas using regression with power
transformation by Andreasen [60].
Electroencephalographic Procedure
The standard protocol for MMN for the experimental paradigm
and data processing reported by Light et al. was followed [61].
Audiometry testing was used to exclude subjects who could not
detect 40-dB sound pressure level tones at 500, 1000, and 6000 Hz
presented to either ear. Subjects were seated in a comfortable
recliner in a sound-attenuating and electrically shielded booth.
They were instructed to relax and to watch a silent benign cartoon
film presented on a 19-inch LCD monitor screen located at eye
level to reduce eye movements over the session. During the test
session, subjects were closely observed through a video monitor
and EEG for signs of sleep or slow wave activity. When
encountered, the experimenter spoke briefly to wake up the
subject.
The auditory stimuli were generated by a Neuroscan STIM
system and were presented to subjects binaurally via foam insert
earphones. The data was recorded by a Neuroscan ACQUIRE
system (NeuroScan, Inc., El Paso, TX). The EEG signals were
recorded with an electrode cap (Quik-Cap, NeuroScan, Inc.,
Charlotte, NC) from 32 scalp locations (10–20 system). Electrodes
placed at the tip of the nose and at Fpz served as the reference and
ground, respectively. Four additional electrodes were located
above and below the left eye and at the outer canthi of both eyes to
monitor blinks and eye movements. Electrode impedances were
kept below 5 kV prior to MMN recording.
An auditory oddball paradigm of duration MMN of approx-
imately 30-min duration was given. The cartoon soundtrack was
turned off and replaced by the experimental 85-dB auditory
stimuli, which were presented at a fixed 500 msec onset-to-onset
asynchrony. The duration of standard stimulation and deviant
stimulation were 50 msec and 100 msec, respectively. Stimuli
occurred in a pseudorandom order with probability of occurrence
0.9 for standard tones and 0.1 for deviant tones. Stimuli signals
were digitized at a rate of 1 kHz and an on-line band-pass filter at
0.5–100 Hz, without 60-Hz notch filter. During testing, online
ERP averages to standard and deviant tones were also acquired to
monitor signal quality and the number of sweeps free of gross
artifacts (defined as 6100 mV across the 2100,500 msec
following stimuli). The MMN session was continued until a
minimum of 225 artifact-free deviant trials had been collected on-
line.
EEG data processing
All data were processed using Neuroscan Edit 4.3 software
(Compumedics USA, Charlotte, North Carolina). Semi-automat-
ed procedures using the Tool Command Language (TCL) batch
processing language began with EOG artifact reduction through a
Figure 2. Effects of age on mismatch negativity. Mean mismatch negativity amplitude (135–205 msec) at electrode Fz reduces with aging. The
reduction rate were not significantly different between healthy control group (open circles and solid regression line) and schizophrenia group
(crosses and dashed regression line).
doi:10.1371/journal.pone.0034454.g002
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uous data files were then epoched 100 msec pre-stimulus to
500 msec post-stimulus. Following linear detrending and baseline
correction to the average pre-stimulus interval, all epochs
containing amplitudes exceeding 650 mV in frontal recording
sites (F7, F8, Fp1, Fp2, F3, F4, and Fz) were automatically
rejected. EEG responses to standard and deviant stimuli were
separately averaged to create a standard ERP and a deviant ERP,
and both were low-pass filtered at 20 Hz (0-phase shift and 24-dB/
octave roll-off) to remove any residual high-frequency artifacts.
MMN waveforms were generated by subtracting the standard
ERP from the deviant ERP [60]. MMN indices were measured as
the mean voltage from 135 to 205 milliseconds [63–66].
Neuropsychological Tests
All subjects received MMN examinations, and most of them
received the neuropsychological test batteries, including the
Continuous Performance Test (CPT) for 114 patients and 70
healthy subjects, Wisconsin Card Sorting Test (WCST) for 115
patients and 71 healthy subjects, and Wechsler Adult Intelligence
Scale Third Edition (WAIS-III) for 102 patients and 72 healthy
subjects [67]. The detailed procedures of the CPT and WCST
have been described in previous publications. In brief, subjects
completed two 5-minute CPT sessions: the undegraded 1–9 task,
and the 25% degraded 1–9 task [68]. Sensitivity indices indicating
the ability to discriminate target from non-target trials were
calculated (d9 for undegraded CPT and md9 for degraded CPT).
The WCST results were scored as four indices defined in the
WCST manual as: (1) perseverative errors: number of errors that
were perseverative reflecting the tendency towards perseveration;
(2) categories achieved: the number of times 10 consecutive correct
responses were made, reflecting overall success; (3) trials to
complete first category: number of trials needed to complete the
first category; and (4) conceptual level response: proportion of
consecutive correct responses occurring in runs of 3 or more,
reflecting insight to the correct sorting principles [69]. Index scores
of CPT and WCST were transformed to adjusted z score by
adjustment for age, sex and education level based on the data of
the healthy subjects [68,70]. The Chinese version of WAIS-III was
applied [67]. In addition to Verbal IQ, Performance IQ, and Full
Scale IQ scores, several scaled scores of subtests and one
composite secondary index were also used, including (1)
Information: a measure of acquired general knowledge; (2)
Arithmetic: a mental arithmetic task that measures working
memory; (3) Digit Span: measuring working memory free from
distraction; (4) Block Design: reflection of visuospatial and motor
skills; (5) Digit Symbol-coding: assessment of processing speed; (6)
Working Memory Index: a composite index composed of
Arithmetic and Digit Span.
Table 2. Comparison of mismatch negativity amplitudes
between groups.
Control Schizophrenia t value P value Effect size
Fp1 20.4560.51 20.260.39 3.89 ,0.001
* 0.55
Fp2 20.4860.57 20.2160.47 3.63 ,0.001
* 0.52
F7 20.360.48 20.1660.41 2.16 0.032 0.31
F8 20.2360.76 20.0960.63 1.4 0.163 0.21
Fz 20.9660.94 20.4160.69 4.71 ,0.001
* 0.66
F3 20.8260.86 20.3460.63 4.49 ,0.001
* 0.63
F4 20.960.88 20.3960.64 4.76 ,0.001
* 0.66
FT7 20.1860.54 20.0960.45 1.24 0.216 0.18
FT8 20.1260.74 20.0760.48 0.59 0.559 0.09
FC3 20.8760.90 20.3660.67 1.79 0.004 0.63
FC4 20.9960.93 20.4160.66 5.1 ,0.001
* 0.7
FCz 21.0661.03 20.3960.76 5.21 ,0.001
* 0.72
T3 20.00360.48 0.00760.53 0.13 0.900 0.02
T4 0.0960.80 0.0260.56 0.71 0.482 0.1
T5 0.1660.81 0.1360.67 0.3 0.765 0.04
T6 0.2960.66 0.1860.69 1.08 0.280 0.16
C3 20.8360.87 20.3360.69 4.44 ,0.001
* 0.62
C4 20.8860.88 20.460.67 4.32 ,0.001
* 0.61
Cz 20.9661.01 20.3660.75 4.8 ,0.001
* 0.67
TP7 0.2260.58 0.1260.64 1.08 0.279 0.16
TP8 0.2560.64 0.1460.63 1.25 0.214 0.18
CP3 20.6460.80 20.2960.69 3.2 0.002 0.46
CP4 20.6860.85 20.2960.67 3.6 ,0.001
* 0.51
CPz 20.7560.95 20.3160.73 3.61 ,0.001
* 0.51
P3 20.4360.78 20.1860.67 2.41 0.017 0.35
P4 20.4360.81 20.2160.65 2.12 0.036 0.31
Pz 20.560.86 20.2260.71 2.44 0.016 0.23
A1 0.4460.48 0.1960.59 3.04 0.003 0.44
A2 0.4960.48 0.2560.58 2.96 0.003 0.43
O1 0.160.58 0.0860.75 0.17 0.865 0.03
O2 0.1360.63 0.0760.75 0.62 0.535 0.09
Oz 0.0660.66 0.0760.76 0.08 0.934 0.01
*Significant difference between controls and patients with schizophrenia
(significance level at 0.0016 after Bonferroni’s correction).
Effect size was the standardized mean difference between groups (Cohen’s d).
doi:10.1371/journal.pone.0034454.t002
Table 3. Correlation between MMN and neuropsychological
tests.
MMN mean amplitude at Fz
Neuropsychological tests Correlation coefficient P value
d92 0.003 0.963
md9 0.023 0.758
Perseverative errors 20.098 0.188
Conceptual level response 0.101 0.173
Categories achieved 0.067 0.364
Trials to complete first category 0.028 0.703
Arithmatics 0.046 0.545
Digit span 0.023 0.761
Information 0.061 0.430
Digit symbol 20.079 0.304
Block design 20.035 0.644
Working memory index 0.082 0.284
Verbal IQ 0.091 0.236
Performance IQ 0.094 0.219
Full IQ 0.059 0.443
Pearson’s partial correlation, controlling for age and affected status.
doi:10.1371/journal.pone.0034454.t003
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Statistical analysis was conducted with the SAS software
package, version 9.2 (SAS Institute Inc., Cary, NC, USA). A
two-sided p-value less than or equal to 0.05 was regarded to be
statistically significant. Continuous data and categorical data were
presented with mean6standard deviation (SD) and frequency
(percentage), respectively. The Student’s t-test and chi-square test
were used to compare data between groups. Mixed-model
repeated-measures ANOVA was applied for two analyses on the
comparison of MMN between patients and controls. The first
analysis examined MMN amplitudes recorded from all electrodes
over the scalp, with the 32 electrodes as the within-subject factor.
The second analysis was focused on midline electrodes, with
electrode site (Fz, FCz, Cz, CPz, Pz, and Oz) as the within-subject
factor. Group was the only between-subject factor, and age was
the only covariate. Huynh-Feldt corrections were applied when
the degree of freedom was more than 1. The correlation between
MMN at electrode Fz and the neuropsychological tests were
explored by Pearson’s partial correlation, controlling for covariates
significantly associated with MMN.
To identify the predictive factors for schizophrenia, multivariate
logistic regression models were applied to find parsimonious
regression models that fit the observed data. The MMN value at
each electrode and all neuropsychological indices listed were
included as potential predictive variables. Then stepwise variable
selection procedure was used, where the significance levels for
entry and for stay were set to 0.15 initially, and then reduced to
0.05 to identify the best final model. Both the goodness of fit
(GOF) measures (the percentage of concordant pairs and adjusted
generalized R2) and the GOF tests (deviance GOF test, Pearson
chi-squared GOF test, and Hosmer-Lemeshow GOF test) were
used to assess the GOF for the fitted model. The percentage of
concordant pairs indicated the proportion of ‘‘concordant’’ pairs
where case (i.e., the observed binary response is 1) had the highest
predicted event probability among all possible case-control pairs.
A larger percentage of concordant pairs suggested a better fit of
the logistic model. Larger p values were preferred for the three
GOF tests when the null hypothesis was that the logistic regression
model fit the observed binary data well. Finally, statistical tools for
regression diagnostics such as residual analysis, detection of
influential cases, and check for multicollinearity were applied
[71,72].
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